A Cross-sectional Study to Evaluate the Prevalence of HPV in Gay and Bisexual Men Aged 16-20 Years in Australia
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Human Papillomavirus Infection
- 发起方
- Monash University
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Prevalence of quadrivalent vaccine HPV types
- 状态
- 招募中
- 最后更新
- 3年前
概览
简要总结
Anal cancer is overrepresented among gay, bisexual and other men who have sex with men (MSM), particularly those living with HIV. Australia was the first country to introduce a publicly funded national HPV vaccination program in 2007. This program was expanded to include schoolboys aged 12-13 years in 2013; with a 2-year catch-up for boys aged up to 15 years. In 2018, the 9-valent vaccine (covering genotypes 6/11/16/18/31/33/45/52/58) replaced the 4-valent vaccine in the national program.
The goal of the HYPER3 study is to determine the prevalence of anal, genital and oral HPV among 200 young gay and bisexual men aged 16-20 years who were eligible for the school-based 9-valent vaccination.
Participants will be required to complete a questionnaire and provide samples for HPV testing. No follow-up visits will be required.
研究者
入排标准
入选标准
- •Men aged 16 to 20 (i.e. men aged 16-18 years in 2023; men aged 16-19 years in 2024; and men aged 16-20 years in 2025 will be recruited. This is to ensure these men would have been eligible for the 9-valent school-based HPV program)
- •Same-sex attracted
- •Residing in Australia since 2018
排除标准
- •Unable to complete all study requirements in English
结局指标
主要结局
Prevalence of quadrivalent vaccine HPV types
时间窗: Baseline
The oral, penile and anal prevalence of quadrivalent vaccine types (6, 11, 16 and 18)
Prevalence of nonavalent vaccine HPV types
时间窗: Baseline
The oral, penile and anal prevalence of nonavalent vaccine types (6, 11, 16, 18, 31,33, 45, 52 and 58)
Prevalence of type-specific HPV types
时间窗: Baseline
The oral, penile and anal prevalence of type-specific HPV types